Month: April 2021

Verkkokauppa.com Oyj        PRESS RELEASE         23.4.2021 at 7.50 EET Verkkokauppa.com to build a world-class automated urban logistics hub in Jätkäsaari, Helsinki Verkkokauppa.com will invest in the logistics automation of the warehouse located in connection to the Jätkäsaari megastore in Helsinki. The investment is the largest in the company’s history and once finalized, will enable future growth, cost savings and improved customer experience through wider assortment, better product availability and faster deliveries. The first phase of the investment is to build a fully automated AutoStore® small item warehouse. The building of this warehouse will commence this summer and to be completed early 2022. The automated robot warehouse will significantly improve the efficiency of space utilization while enabling even faster deliveries and...

Verkkokauppa.com Oyj        LEHDISTÖTIEDOTE        23.4.2021        klo 7.50 Verkkokauppa.com rakentaa Jätkäsaareen maailmanluokan automatisoidun logistiikkakeskuksen Verkkokauppa.com investoi Helsingissä sijaitsevan Jätkäsaaren myymälän yhteydessä olevan varaston logistiikka-automaatioon. Investointi on yhtiön historian suurin, ja valmistuessaan tukee Verkkokauppa.comin kasvua, tuo kustannussäästöjä sekä tarjoaa paremman asiakaskokemuksen laajemman valikoiman, parantuneen tuotesaatavuuden ja nopeampien toimitusten kautta. Investoinnin ensimmäinen vaihe on täysin automatisoidun pienartikkelivaraston, AutoStoren®, rakentaminen. Työ käynnistyy tulevana kesänä, ja sen odotetaan olevan valmis alkuvuodesta 2022. Automatisoitu robottivarasto hyödyntää varastotilaa merkittävästi tehokkaammin ja mahdollistaa entistäkin nopeammat toimitukset ja...

Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium; 23 April 2021; 06.01 CET; – Galapagos NV (Euronext & Nasdaq: GLPG) today report that their collaboration partner Gilead Sciences K.K. (“Gilead”) and Eisai Co., Ltd. (“Eisai”) today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis (UC). Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis. This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study evaluating...

Aanvraag is gebaseerd op fase 2b/3 SELECTION-studieresultaten bij patiënten met matige tot ernstige actieve colitis ulcerosa   Mechelen, België; 23 april 2021; 06.01 CET; – Galapagos NV (Euronext & Nasdaq: GLPG) meldt vandaag dat haar samenwerkingspartner Gilead Sciences K.K. (hierna genoemd “Gilead”) en Eisai Co., Ltd. (“Eisai”) vandaag bekend hebben gemaakt dat Gilead een aanvraag heeft ingediend bij het Japanse Pharmaceuticals and Medical Devices Agency (PMDA) voor de goedkeuring van filgotinib voor een bijkomende indicatie voor de behandeling van patiënten met matige tot ernstige actieve colitis ulcerosa (CU). Filgotinib is een nieuwe orale Janus kinase (JAK)–remmer die in september 2020 in Japan werd goedgekeurd voor de behandeling van reumatoïde artritis. Deze meest recente indiening bij de regelgevende instanties is...

Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it completed an additional potentially non-dilutive convertible debt offering with an institutional investor, which provides $25 million of immediately available capital. The note has a two-year maturity, bears interest at the rate of 10% per annum and is secured by all assets of the Company, excluding its intellectual property. The note may be converted at the option of the investor into shares of the Company’s common stock at a conversion price of $10.00 per share. Chris Recknor, M.D.,...

LINDON, Utah, April 22, 2021 (GLOBE NEWSWIRE) — Profire Energy, Inc. (NASDAQ: PFIE), a technology company (the “Company”) that provides solutions which enhance the efficiency, safety, and reliability of industrial combustion appliances, will hold a conference call on Thursday, May 6, 2021 at 1:00 p.m. ET to discuss results for its 2021 first quarter ended March 31, 2021. Financial results are expected to be filed with the Securities and Exchange Commission and reported in a press release prior to the conference call. Profire Energy Co-CEO and CFO Ryan Oviatt and Co-CEO Cameron Tidball will host the presentation, followed by a question and answer period. Date: Thursday, May 6, 2021Time: 1:00 p.m. ET (11:00 a.m. MT)Toll-free dial-in number: 1-855-327-6837International dial-in number: 1-631-891-4304 The conference call...

PONTE VEDRA, Fla., April 22, 2021 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the pricing of its upsized initial public offering of an aggregate of 11,250,000 shares of its common stock, 6,250,000 of which are being sold by Treace and 5,000,000 of which are being sold by certain selling stockholders, at a public offering price of $17.00 per share. The gross proceeds from the offering to Treace are expected to be approximately $106.3 million before deducting underwriting discounts and commissions and other offering expenses payable by Treace. Treace will not receive any proceeds from the sale of shares by the selling stockholders. In...

PONTE VEDRA, Fla., April 22, 2021 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the pricing of its upsized initial public offering of an aggregate of 11,250,000 shares of its common stock, 6,250,000 of which are being sold by Treace and 5,000,000 of which are being sold by certain selling stockholders, at a public offering price of $17.00 per share. The gross proceeds from the offering to Treace are expected to be approximately $106.3 million before deducting underwriting discounts and commissions and other offering expenses payable by Treace. Treace will not receive any proceeds from the sale of shares by the selling stockholders. In...

BEIJING, CHINA, April 22, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Infobird Co., Ltd (“Infobird”), a software-as-a-service provider of innovative AI-powered, or artificial intelligence enabled, customer engagement solutions in China, announces the closing of its underwritten initial public offering of 6,250,000 ordinary shares at a public offering price of $4.00 per share, before underwriting discounts and commissions, resulting in gross proceeds of $25,000,000, before underwriting discounts and commissions and offering expenses. The offering was conducted on a firm commitment basis. All of the ordinary shares were offered by Infobird. The ordinary shares were approved for listing on The Nasdaq Capital Market and commenced trading under the ticker symbol “IFBD” on April 20, 2021. WestPark Capital, Inc. (“WestPark Capital”) acted...